Ramucirumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), HAS (France) and PBAC (Australia) recommended or restricted ramucirumab, while AWMSG (Wales), CIPM (Spain) and CONITEC (Brazil), among others, did not recommend it.
Assessment has run over 10.3 years, from 8 Jan 2015 at AWMSG (Wales) to 7 May 2025 at CONITEC (Brazil).
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for ramucirumab, 5 submissions were never made and 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
Against its own class, ramucirumab is an outlier: 44% of its decisive outcomes were positive, where molecules sharing ATC class L01F average 73%.
The programme is broad: 14 distinct indication wordings are recorded for ramucirumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 31 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess ramucirumab, on 8 Jan 2015; CONITEC (Brazil) did not open a file until 7 May 2025 — an unusually long tail of 10.3 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 8 years in total.
7 of the 9 agencies here assessed ramucirumab more than once, NYE METODER (Norway) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for ramucirumab.
The full ledger for ramucirumab reads 9 not recommended, 7 recommended, 5 non-submission and 3 other, with 7 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 7 May 2025 | Tratamento de adultos diagnosticados com câncer de estômago ou junção gastroesofágica avançado ou metastático refratário… | not incorporated | source |
| NYE METODER (Norway) | 27 Apr 2025 | Som monoterapi til behandling av leverkreft hos pasienter med alfaføtoprotein ≥ 400 ng/ml, etter behandling med sorafeni… | decision recorded | source |
| PBAC (Australia) | 2021 | Advanced gastric or gastro-oesophageal junction adenocarcinoma | Recommendation extended for 6 months | source |
| SMC (Scotland) | 7 Jun 2021 | In combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth fact… | not recommended | source |
| CIPM (Spain) | 3 Feb 2021 | Indicaciones terapéuticas autorizadas: Cáncer gástrico: Cyramza en combinación con paclitaxel está indicado para el trat… | not financed by the SNS · art. 92 d, e | source |
26 further decisions for ramucirumab, across 7 agencies, are not shown here. They link to 22 further source documents.
Related molecules
- amivantamab — divergent outcome (not recommended vs recommended) on a shared indication
- osimertinib — divergent outcome (not recommended vs recommended) on a shared indication
- gefitinib — divergent outcome (not recommended vs recommended) on a shared indication
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
Coverage: 31 decisions for ramucirumab from 9 agencies, 2015 to 2025. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.